专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060222644A1 Humanized anti-Lymphotoxin beta receptor antibodies 失效
标题翻译：人源化抗淋巴毒素β受体抗体
公开(公告)号：US20060222644A1
公开(公告)日：2006-10-05
申请号：US11021819
申请日：2004-12-23
申请人： Ellen Garber , Kenneth Simon , Jose Saldanha
发明人： Ellen Garber , Kenneth Simon , Jose Saldanha
IPC分类号： A61K39/395 , C12N5/06 , C07K16/44
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
摘要翻译：本发明涉及针对淋巴毒素β受体（LT-β-R）特异性的人源化抗体，产生这些抗体的细胞系，由抗体制备的免疫化学物质，以及使用该抗体的诊断方法。本发明还涉及在治疗方法中单独或与化学治疗剂组合使用抗体。

2. 发明授权

US07429645B2 Humanized anti-lymphotoxin beta receptor antibodies 失效
标题翻译：人源化抗淋巴毒素β受体抗体
公开(公告)号：US07429645B2
公开(公告)日：2008-09-30
申请号：US11021819
申请日：2004-12-23
申请人： Ellen Garber , Kenneth Simon , Jose William Saldanha
发明人： Ellen Garber , Kenneth Simon , Jose William Saldanha
IPC分类号： C12P21/08 , C07K16/00 , A61K39/395 , C12P21/04 , C07H21/04
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
摘要翻译：本发明涉及针对淋巴毒素β受体（LT-β-R）特异性的人源化抗体，产生这些抗体的细胞系，由抗体制备的免疫化学物质，以及使用该抗体的诊断方法。本发明还涉及在治疗方法中单独或与化学治疗剂组合使用抗体。

3. 发明申请

US20050255102A1 Anti-alphavbeta6 antibodies 有权
标题翻译：抗alphavbeta6抗体
公开(公告)号：US20050255102A1
公开(公告)日：2005-11-17
申请号：US10507662
申请日：2003-03-13
申请人： Shelia Violette , Paul Weinreb , Kenneth Simon , Dean Sheppard , Diane Leone
发明人： Shelia Violette , Paul Weinreb , Kenneth Simon , Dean Sheppard , Diane Leone
IPC分类号： C12N15/09 , A61K39/395 , A61K47/48 , A61K51/10 , A61P1/16 , A61P11/00 , A61P13/12 , A61P17/02 , A61P17/06 , A61P35/00 , C07K7/08 , C07K14/00 , C07K16/18 , C07K16/28 , C12N20060101 , C12N5/10 , C12N5/12 , C12Q1/02 , G01N33/574 , G01N33/68
CPC分类号： C07K16/2839 , A61K47/48507 , A61K47/48561 , A61K47/48623 , A61K47/68 , A61K47/6835 , A61K47/6849 , A61K47/6851 , A61K47/6865 , A61K51/1027 , A61K51/1066 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/205
摘要： Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.
摘要翻译：特异性结合M.96的单克隆抗体。还包括使用这些抗体治疗具有或具有006介导的疾病的风险的哺乳动物或诊断％Q介导的疾病的方法。

4. 发明授权

US08349324B2 Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues 有权
标题翻译：通过合理修饰互补决定残基来人源化免疫球蛋白可变区的方法
公开(公告)号：US08349324B2
公开(公告)日：2013-01-08
申请号：US12628898
申请日：2009-12-01
申请人： Alexey Alexandrovich Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman Van Vlijmen
发明人： Alexey Alexandrovich Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman Van Vlijmen
IPC分类号： A61K39/395
CPC分类号： C07K1/00 , C07K16/00 , C07K16/2842 , C07K16/30 , C07K16/465 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
摘要翻译：本发明至少部分地基于以下发现，即可以使用非人供体抗体CDR残基的战略修饰来使抗体人源化。这样的修饰调节供体抗体CDR和包含CDR移植抗体的可变结构域的人受体抗体框架区之间的3D结构拟合。而现有技术的人源化方法依赖于进行框架取代（其中所选择的人类框架残基反向到存在于非人供体抗体中的相应氨基酸残基），本发明至少部分地基于人源化抗体的方法，其中选择的CDR残基和任选相邻的FR残基被改变以适应供体和受体抗体之间的FR氨基酸序列的差异。

5. 发明申请

US20110073606A1 Apparatus for the secure transport of containers 审中-公开
标题翻译：用于安全运输集装箱的装置
公开(公告)号：US20110073606A1
公开(公告)日：2011-03-31
申请号：US12807952
申请日：2010-09-17
申请人： Kenneth Simon
发明人： Kenneth Simon
IPC分类号： B65D90/00
CPC分类号： B60R11/00 , B60P3/055 , B60R2011/0012 , B60R2011/0078
摘要： An apparatus that allows for safe and secure transport of a tank, canister, container or cylinder in the upright position on the seat in a vehicle, using the three point seat belt mechanism provided in the vehicle. The primary use was directed toward transportation of a 20 pound propane tank. An apparatus consisting of a body and a bracket, attachment or mechanism that holds the seats belts in place around the tank or cylinder. The body comes into contact with the tank and the brackets, attachments or mechanism that are a part of the body, allow for the three point seat belt straps to be placed in a proper position to hold the tank against the car seat in the car. There is also a retaining strap that goes around the value area of the tank to hold it in place.
摘要翻译：一种装置，其使用设置在车辆中的三点式安全带机构，能够使车辆中的座椅上的直立位置的罐，罐，容器或汽缸安全地和可靠地运送。主要用途是运送20磅丙烷罐。一种由主体和支架组成的装置，附件或机构，其将座椅皮带保持在罐或圆筒周围的适当位置。身体与坦克接触，作为身体的一部分的支架，附件或机构，允许将三点式安全带带放置在适当的位置，以将坦克抵靠在汽车中的汽车座椅上。还有一个挡土墙围绕坦克的价值区域，以将其固定到位。

6. 发明授权

US07678371B2 Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues 有权
标题翻译：通过合理修饰互补决定残基来人源化免疫球蛋白可变区的方法
公开(公告)号：US07678371B2
公开(公告)日：2010-03-16
申请号：US11369641
申请日：2006-03-06
申请人： Alexey Alexandrovich Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman Van Vlijmen
发明人： Alexey Alexandrovich Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman Van Vlijmen
IPC分类号： A61K39/00
CPC分类号： C07K1/00 , C07K16/00 , C07K16/2842 , C07K16/30 , C07K16/465 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
摘要翻译：本发明至少部分地基于以下发现，即可以使用非人供体抗体CDR残基的战略修饰来使抗体人源化。这样的修饰调节供体抗体CDR和包含CDR移植抗体的可变结构域的人受体抗体框架区之间的3D结构拟合。而现有技术的人源化方法依赖于进行框架取代（其中所选择的人类框架残基反向到存在于非人供体抗体中的相应氨基酸残基），本发明至少部分地基于人源化抗体的方法，其中选择的CDR残基和任选相邻的FR残基被改变以适应供体和受体抗体之间的FR氨基酸序列的差异。

7. 发明申请

US20100093980A1 Methods of Humanizing Immunoglobulin Variable Regions Through Rational Modification Of Complementarity Determining Residues 有权
标题翻译：通过合理修饰互补性确定残留物免疫球蛋白可变区人源化方法
公开(公告)号：US20100093980A1
公开(公告)日：2010-04-15
申请号：US12628898
申请日：2009-12-01
申请人： Alexey Alexandrovich Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman van Vlijmen
发明人： Alexey Alexandrovich Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman van Vlijmen
IPC分类号： C07K16/00
CPC分类号： C07K1/00 , C07K16/00 , C07K16/2842 , C07K16/30 , C07K16/465 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
摘要翻译：本发明至少部分地基于以下发现，即可以使用非人供体抗体CDR残基的战略修饰来使抗体人源化。这样的修饰调节供体抗体CDR和包含CDR移植抗体的可变结构域的人受体抗体框架区之间的3D结构拟合。而现有技术的人源化方法依赖于进行框架取代（其中所选择的人类框架残基反向到存在于非人供体抗体中的相应氨基酸残基），本发明至少部分地基于人源化抗体的方法，其中选择的CDR残基和任选相邻的FR残基被改变以适应供体和受体抗体之间的FR氨基酸序列的差异。

8. 外观设计

USD583188S1 Cake mold 有权
标题翻译：蛋糕模具
公开(公告)号：USD583188S1
公开(公告)日：2008-12-23
申请号：US29317222
申请日：2008-04-24
申请人： Kenneth Simon
设计人： Kenneth Simon

9. 发明申请

US20060258852A1 Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues 有权
公开(公告)号：US20060258852A1
公开(公告)日：2006-11-16
申请号：US11369641
申请日：2006-03-06
申请人： Alexey Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman van Vlijmen
发明人： Alexey Lugovskoy , Karl Hanf , You Li , Kenneth Simon , Herman van Vlijmen
IPC分类号： C07K16/44 , G06F19/00
CPC分类号： C07K1/00 , C07K16/00 , C07K16/2842 , C07K16/30 , C07K16/465 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式